Catalent snaps up Promethera's cell therapy subsidiary, complete with a Belgian plant to help scale plasmid DNA efforts
Riding a wave from its work on the Covid-19 response, CDMO giant Catalent has been expanding rapidly in next-gen cell therapies as it gets prepped for a future boom. After a couple of snap expansions at its Belgian campus, Catalent is now adding another facility at the site as part of its plan to bolster its EU hub.
Catalent has acquired Promethera’s Hepatic Cell Therapy Support SA subsidiary and its 32,40-square-foot facility in Gosselies, Belgium, part of the New Jersey drugmaker’s continued expansion plans in the country, the companies said Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,900+ biopharma pros reading Endpoints daily — and it's free.